Influenza Diagnostics

Influenza Diagnostics

Global Influenza Diagnostics Market to Reach US$4.9 Billion by 2030

The global market for Influenza Diagnostics estimated at US$3.4 Billion in the year 2023, is expected to reach US$4.9 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the POCT End-Use segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$912.5 Million While China is Forecast to Grow at 8.0% CAGR

The Influenza Diagnostics market in the U.S. is estimated at US$912.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Influenza Diagnostics Market - Key Trends & Drivers Summarized>What Are the Current Technologies in Influenza Diagnostics?
Influenza diagnostics have become critical for effective healthcare delivery, especially in managing seasonal outbreaks and potential pandemics. Current technologies in influenza diagnostics include rapid influenza diagnostic tests (RIDTs), reverse transcription-polymerase chain reaction (RT-PCR), and viral cultures. RIDTs offer the advantage of speed, providing results in less than 30 minutes, which facilitates swift clinical decisions. However, RT-PCR is the gold standard for influenza diagnostics due to its high sensitivity and specificity, capable of distinguishing between different influenza strains. Viral culture, while less common due to its longer turnaround time, remains an important tool for epidemiological studies and vaccine development. Recent advancements also include the integration of multiplex assays that can detect influenza alongside other respiratory pathogens, enhancing the efficiency and comprehensiveness of testing.

How Are Patient Demands Transforming Influenza Diagnostics?
As healthcare consumers become more informed, there is a growing demand for quicker, more accurate diagnostic methods that can be accessed conveniently. This shift is driving the development of point-of-care (POC) tests that can be administered in various settings outside the traditional laboratory environment, such as pharmacies or at home. These tests are designed to be user-friendly, requiring minimal technical skills and providing rapid results to reduce the waiting period and accelerate the initiation of appropriate treatments. This patient-centric approach not only improves individual health outcomes but also aids in controlling the spread of the virus in community settings, highlighting the importance of accessibility and speed in influenza diagnostics.

What Impact Does Technology Have on the Evolution of Influenza Diagnostics?
Technological innovation is a key driver in the evolution of influenza diagnostics. The emergence of digital health technologies, including telehealth and mobile health apps, is playing a crucial role in the management of influenza. These technologies allow for remote diagnosis and monitoring, which is particularly beneficial during peak flu seasons or pandemics when healthcare facilities are overwhelmed. Additionally, advancements in genetic sequencing and bioinformatics have improved the accuracy and speed of strain identification, which is vital for effective treatment and vaccination strategies. The ongoing development of biosensors and wearable devices that can detect early symptoms of influenza represents another promising frontier, potentially enabling even earlier detection and intervention.

Growth in the Influenza Diagnostics Market Is Driven by Several Factors…
The growth in the influenza diagnostics market is driven by several factors, including the increased global incidence of seasonal influenza and heightened awareness of pandemic threats. Rapid urbanization and international travel contribute to the faster spread of the virus, necessitating robust diagnostic solutions globally. Advances in diagnostic technologies, particularly in rapid testing and genetic analysis, have significantly improved the response time and accuracy of influenza diagnostics. Government initiatives and funding for infectious disease control further support the expansion of the diagnostics market. Additionally, the integration of artificial intelligence and machine learning in diagnostic processes enhances data analysis and interpretation, leading to more precise and predictive diagnostics. As healthcare systems worldwide prioritize preventive care and early intervention, the demand for advanced, rapid influenza diagnostic solutions continues to rise, ensuring sustained growth in this sector.

Select Competitors (Total 38 Featured) -

• Alere, Inc.
• Analytik Jena AG
• Becton, Dickinson and Company
• DiaSorin SpA
• F. Hoffmann-La Roche AG
• Luminex Corporation
• Meridian Bioscience, Inc.
• Quidel Corporation
• SA Scientific, Ltd.
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.